Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine, Lidocaine, or Diltiazem to balance ECG effects of Dofetilide or Moxifloxacin
NCT02308748Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of mexiletine, Lidocaine Hydrochloride Injection, without epinephrine and diltiazem in long QT syndrome (LQTS), sponsored by Food and Drug Administration. Started May 2014; status: completed.
02
Drugs
mexiletineLidocaine Hydrochloride Injection, without epinephrinediltiazem
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT02308748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308748.